#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Isodicentric chromosome 15 syndrome Brain injury Anti-HLA antibody test positive PIK3CA related overgrowth spectrum Factor VIII deficiency Pancreatic carcinoma B-cell small lymphocytic lymphoma refractory Pneumonia Epidermolysis bullosa Monogenic diabetes Hodgkin's disease refractory Burkitt's lymphoma refractory T-cell type acute leukaemia Cortical dysplasia Bone marrow disorder More trials…

    Learn about Rare Diseases

    Isodicentric chromosome 15 syndrome Congenital generalised lipodystrophy – Life with Disease Medulloblastoma – Basic Information Angelman’s syndrome – Diagnostics Chronic granulomatous disease – Diagnostics Paraneoplastic neurological syndrome – Treatment Atypical haemolytic uraemic syndrome – Treatment Pleomorphic leiomyosarcoma – Treatment Atypical haemolytic uraemic syndrome Wolfram syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ALE.P03 Magnesium Chloride Ucart20X22 Betamethasone Tetracosactide Vobramitamab Duocarmazine Busulfan Relatlimab Alisertib Sodium Oseltamivir Zoledronic Acid Filgrastim Aspartic Acid ALE1 Vilanterol Nitrofurantoin MRNA-1345 Disodium Folinate Exidavnemab Hct116-B More therapies…

    Learn about Your Condition

    Erythema Colorectal cancer stage III Noninfective chorioretinitis Ependymoma malignant Anal squamous cell carcinoma Malignant melanoma stage IV Mucopolysaccharidosis I Thrombolysis Lung transplant Eructation Behavioural addiction Osteonecrosis of jaw Neurofibromatosis Follicular lymphoma Pruritus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Asklepios Kliniken Hamburg GmbH

Asklepios Kliniken Hamburg GmbH

Eissendorfer Pferdeweg 52, Heimfeld, Hamburg, 21075, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Domvanalimab
    Austria Belgium France Germany Italy The Netherlands +2

  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Austria Belgium Czechia Denmark Finland France +10

  • Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Atezolizumab
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Regorafenib
    Belgium France Germany Hungary Poland Portugal +1

  • Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Isatuximab
    Germany

  • Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Anal cancer stage II
    • Anal cancer stage III
    Investigated Drugs:
    • Durvalumab
    Austria Germany

  • Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma of colon
    • Colon cancer stage III
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Atezolizumab
    • Mycobaterium Obuense, Strain Nctc 13365, Heat-Killed
    Germany

  • Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetuximab
    • Docetaxel
    • Methotrexate
    Belgium Czechia France Germany Greece Hungary +6

  • Study on the Effectiveness and Safety of Cisplatin, Carboplatin, Etoposide, and Durvalumab in Patients with Limited Stage Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Germany

  • Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Isatuximab
    • Lenalidomide
    Germany

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bleomycin Sulfate
    • Brentuximab Vedotin
    • Cyclophosphamide Monohydrate
    Austria Denmark Germany The Netherlands Norway Sweden
Previous Page
1 … 6 7 8 9 10 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!